23 results match your criteria: "Susrut Eye Foundation & Research Centre[Affiliation]"
Ophthalmol Retina
October 2024
Department of Vitreoretinal Diseases, Susrut Eye Foundation and Research Centre, Berhampore, West Bengal, India.
Ophthalmology
April 2024
International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom; Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Tel-Aviv University, Tel-Aviv, Israel.
Purpose: To describe the clinical presentation and treatment outcomes of children who received a diagnosis of retinoblastoma in 2017 throughout Asia.
Design: Multinational, prospective study including treatment-naïve patients in Asia who received a diagnosis of retinoblastoma in 2017 and were followed up thereafter.
Participants: A total of 2112 patients (2797 eyes) from 96 retinoblastoma treatment centers in 33 Asian countries.
Oman J Ophthalmol
June 2023
Department of Cataract and Anterior Segment, Susrut Eye Foundation and Research Institute, Kolkata, West Bengal, India.
Introduction: The presence of preoperative posterior capsular dehiscence in posterior polar cataracts (PPCs) increases the chances of intraoperative posterior capsular rent. Our study aims to demonstrate the efficacy of preoperative anterior segment optical coherence tomography (ASOCT) to predict intraoperative posterior capsular rupture (PCR) in PPC.
Materials And Methods: This was an observational study including patients within 25-75 years of age, having PPC, undergoing phacoemulsification.
Clin Ophthalmol
August 2023
Novartis Pharma AG, Basel, Switzerland.
Objective: To evaluate the short-term effectiveness and safety outcomes following brolucizumab treatment in patients with neovascular age-related macular degeneration (nAMD) as a part of real-world clinical practice in India.
Methods: This was a retrospective, observational, multicentre study including patients (≥50 years old) diagnosed with nAMD. Anonymized data of the patients receiving the first dose of brolucizumab intravitreal injection (IVI) who were either treatment-naïve or previously treated with a single or a combination of other anti-VEGF IVIs were included.
Indian J Ophthalmol
June 2023
Sangam Netralya, Mohali, Punjab, India.
Purpose: Glaucoma is the second leading cause of blindness worldwide, affecting more than 64 million people aged 40-80. The best way to manage primary open-angle glaucoma (POAG) is by lowering the intraocular pressure (IOP). Netarsudil is a Rho kinase inhibitor, the only class of antiglaucoma medications that reorganizes the extracellular matrix to improve the aqueous outflow through the trabecular pathway.
View Article and Find Full Text PDFOman J Ophthalmol
March 2022
Susrut Eye Foundation and Research Centre, Kolkata, West Bengal, India.
Indian J Ophthalmol
March 2022
Institute of Ophthalmology, Jawaharlal Nehru Medical, College, AMU, Aligarh, UP; Orbit Oculoplasty, Reconstructive and Aesthetic Service, Aditya Birla Sankara Nethralaya, Kolkata, West Bengal, India.
Purpose: Fibrin glue was used for anastomosis of lacrimal sac and nasal mucosal flaps and was compared with the conventional suture technique in external dacryocystorhinostomy.
Methods: A prospective interventional randomized control study in which 50 consecutive patients of primary acquired nasolacrimal duct obstruction (PANDO) were equally allocated into two groups. The case group underwent glued technique of external dacryocystorhinostomy (Ext DCR) in which fibrin glue was used for the apposition of the anterior lacrimal sac and nasal mucosal flaps.
Indian J Ophthalmol
February 2022
Department of Retina, Susrut Eye Foundation and Research Centre, Kolkata, West Bengal, India.
The whole world waiting for the elimination of COVID-19. This is a short series of three cases that presented with optic neuritis. On further inquiry, all had received the Covishield vaccine within 5-12 days just before the presentation, with no history of COVID-19 positive RT-PCR.
View Article and Find Full Text PDFEye (Lond)
February 2023
Division of Ophthalmology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Indian J Ophthalmol
November 2021
Viitreoretinal Services, Aravind Eye Hospital, Puducherry, India.
Purpose: To derive consensus statements for surgical management of proliferative diabetic retinopathy (PDR) for vitreoretinal (VR) surgeons.
Methods: Thirteen prolific VR surgeons representing all regions of India were invited to participate in a 42-point questionnaire based on the Delphi methodology describing various surgical scenarios commonly encountered in PDR. Consensus was derived using predefined robust analytics.
Eur J Ophthalmol
July 2021
Dr R P Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
There have been major changes in our understanding of choroidal diseases in the last decade owing to multiple retinal and choroidal imaging related advances. A major conceptual pivot is establishment of pachychoroid and its spectrum of clinical disorders: pachychoroid pigment epitheliopathy, central serous chorioretinopathy, pachychoroid neovasculopathy, polypoidal choroidal vasculopathy/aneurysmal type 1 neovascularization, peripapillary pachychoroid syndrome, and focal choroidal excavation. However, considerable overlaps in manifestations and therapeutics of these disorders make differentiation amongst them difficult.
View Article and Find Full Text PDFOcul Oncol Pathol
June 2021
Laboratory Services, Dr Shroff's Charity Eye Hospital, New Delhi, India.
Retinal hemangioblastoma (RH) is the earliest and most common clinical manifestation in Von Hippel-Lindau (VHL) disease. RH can also present in isolation without any evidence of VHL. Clinical course of RH can be stationary or progress to exudation and chronic retinal detachment requiring surgical intervention.
View Article and Find Full Text PDFInt J Retina Vitreous
March 2021
Clinical Development & Medical Affairs, Intas Pharmaceuticals Ltd. (Biopharma), Ahmedabad, Gujarat, India.
Background: Razumab™ (world's first biosimilar ranibizumab) is approved for several macular disorders including wet age-related macular degeneration (AMD). We evaluated the safety and efficacy of biosimilar ranibizumab in wet AMD.
Methods: This prospective, multicentre, rAnibizumab bioSimilar Safety Efficacy postmarkeTing (ASSET) study enrolled patients aged ≥ 50 years with wet AMD having best-corrected visual acuity (BCVA) between 20/40 and 20/320.
Indian J Ophthalmol
April 2020
Vitreoretina Services, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Pondicherry, India.
Purpose: To assess trends in antibiotic sensitivity of pseudomonas and compare multidrug resistance (MDR) between Pseudomonas endophthalmitis cases presenting in two consecutive 6-year time frames in a tertiary center in South India.
Methods: This is a retrospective comparative series of all Pseudomonas endophthalmitis cases treated from June 2004 to May 2016. Microbiological culture results in all endophthalmitis patients were screened for pseudomonas.
Trop Doct
July 2018
5 Assistant Professor, Retina and Uvea Services, Dr RP Centre for Ophthalmic Sciences, 28730 All India Institute of Medical Sciences, New Delhi, India.
BMJ Case Rep
July 2017
Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
This prospective study was performed to find out the profile of newly diagnosed uveitis patients in a tertiary eye hospital in Eastern India over one year from August 2006 to July 2007. One hundred and sixty-one patients were included; 58 patients (36.02%) had anterior uveitis, 21 (13.
View Article and Find Full Text PDFJ Indian Med Assoc
October 2011
Department, Susrut Eye Foundation and Research Centre, Kolkata 700106.
Choroidal haemangioma is a benign tumour with visual acuity diminution due to subretinal fluid accumulation. There are many modalities of treatment of this visually disabling syndrome, some of them being argon laser photocoagulation, cryotherapy, external beam irradiation, proton beam radiotherapy, episcleral plaque radiotherapy and transpupillary thermotherapy. Another new modality of treatment with remarkable success rate is photodynamic therapy.
View Article and Find Full Text PDFA comparative double-blind placebo-controlled clinical trial of a herbal eye drop (itone) was conducted to find out its efficacy and safety in 120 patients with computer vision syndrome. Patients using computers for more than 3 hours continuously per day having symptoms of watering, redness, asthenia, irritation, foreign body sensation and signs of conjunctival hyperaemia, corneal filaments and mucus were studied. One hundred and twenty patients were randomly given either placebo, tears substitute (tears plus) or itone in identical vials with specific code number and were instructed to put one drop four times daily for 6 weeks.
View Article and Find Full Text PDF